AD1801

AD1801 was a **BioArctic** preclinical Alzheimer's disease program directed against **apolipoprotein E** to pursue a disease-modifying approach for sporadic Alzheimer's disease. Based on BioArctic's disclosures, the project was associated with the company's ApoE antibody research effort and appears to have been an **antibody-based biologic**, intended potentially for use either as monotherapy or in combination with other Alzheimer's therapies. No non-code-name active ingredient or brand name was publicly disclosed before the program was ended, and the project was **discontinued in 2022** following a data-driven portfolio decision.